The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Alexander Starodub
Disclosure not yet available
Allen Lee Cohn
Disclosure not yet available
Christy Arrowood
Disclosure not yet available
Sherri Haley
Disclosure not yet available
Michael Morse
Disclosure not yet available
Hope Elizabeth Uronis
Disclosure not yet available
Gerard C. Blobe
Disclosure not yet available
Shiaowen David Hsu
Disclosure not yet available
Yousuf Zafar
Disclosure not yet available
Herbert Hurwitz
Disclosure not yet available